


**LIVEN PHARMA LIMITED**  
**CONDENSED INTERIM STATEMENT OF FINANCIAL POSITION**  
**AS AT DECEMBER 31, 2025**

	Note	Un-audited December 31, 2025 (Rupees)	Audited June 30, 2025 (Rupees)
<b>ASSETS</b>			
<b>Non-current assets</b>			
Property, plant and equipment	7	666,035,692	666,512,380
Intangible assets	8	6,618,800	8,440,679
<b>Total non-current assets</b>		<b>672,654,492</b>	<b>674,953,059</b>
<b>Current assets</b>			
Trade debts	9	6,750,534	9,402,578
Stock in trade	10	121,024,869	123,324,881
Tax refund due from government		141,137	-
Prepayments, deposits and advances	11	7,312,847	7,339,727
Cash and bank balances	12	3,285,518	7,884,396
<b>Total current assets</b>		<b>138,514,905</b>	<b>147,951,582</b>
<b>TOTAL ASSETS</b>		<b>811,169,397</b>	<b>822,904,641</b>
<b>EQUITY AND LIABILITIES</b>			
<b>Share capital and reserves</b>			
<b>Share capital</b>			
Issued, subscribed and paid-up share capital		930,403,670	930,403,670
<b>Capital reserve</b>			
Surplus on revaluation on property, plant and equipment		-	-
<b>Revenue reserve</b>			
Accumulated loss		(298,491,005)	(296,543,276)
<b>TOTAL EQUITY</b>		<b>631,912,665</b>	<b>633,860,394</b>
<b>LIABILITIES</b>			
<b>Non-current liabilities</b>			
Lease liabilities	13	918,988	1,247,868
Long term financing	14	3,584,035	5,098,065
Deferred taxation		71,251,164	92,272,765
<b>Total non-current liabilities</b>		<b>75,754,187</b>	<b>98,618,698</b>
<b>Current liabilities</b>			
Trade and other payables	15	76,223,327	61,720,121
Loan from related parties	16	14,455,411	14,047,263
Running finance		9,144,801	11,185,166
Mark up accrued		360,310	386,020
Current portion of long term liabilities	17	3,318,696	3,086,979
Provision for taxation		-	-
<b>Total current liabilities</b>		<b>103,502,545</b>	<b>90,425,549</b>
<b>TOTAL LIABILITIES</b>		<b>179,256,732</b>	<b>189,044,247</b>
<b>TOTAL EQUITY AND LIABILITIES</b>		<b>811,169,397</b>	<b>822,904,641</b>
<b>CONTINGENCIES AND COMMITMENTS</b>	18		

The annexed notes 1 to 26 form an integral part of these condensed interim financial statements.



Chief Executive



Director



Chief Financial Officer




**LIVEN PHARMA LIMITED**  
**CONDENSED INTERIM STATEMENT OF PROFIT OR LOSS**  
**FOR THE HALF YEAR ENDED DECEMBER 31, 2025**

	Note	HALF YEAR ENDED		QUARTER ENDED	
		Un-audited Dec 31, 2025	Un-audited Dec 31, 2024	Un-audited Dec 31, 2025	Un-audited Dec 31, 2024
		(Rupees)	(Rupees)	(Rupees)	(Rupees)
Revenue		63,380,197	106,035,496	54,559,387	17,125,769
Cost of sales		(41,453,751)	(71,741,867)	(36,564,323)	(7,643,063)
<b>Gross profit</b>		<b>21,926,446</b>	<b>34,293,629</b>	<b>17,995,064</b>	<b>9,482,706</b>
Administrative and general expenses		(18,537,846)	(20,884,951)	(8,982,109)	(16,204,948)
Selling and distribution expenses		(9,395,690)	(2,765,370)	(4,629,811)	(2,765,370)
Other expenses		(24,776,426)	-	(4,055,589)	-
Finance cost		(1,305,007)	(3,150)	(670,371)	(3,150)
<b>Operating (loss) / profit</b>		<b>(32,088,523)</b>	<b>10,640,158</b>	<b>(342,815)</b>	<b>(9,490,762)</b>
Other income	19	9,988,369	119,295,890	9,984,337	-
<b>(Loss) / profit before levies and taxation</b>		<b>(22,100,154)</b>	<b>129,936,048</b>	<b>9,641,522</b>	<b>(9,490,762)</b>
Levies	20	(869,176)	-	(681,992)	-
<b>(Loss) / profit before taxation</b>		<b>(22,969,330)</b>	<b>129,936,048</b>	<b>8,959,529</b>	<b>(9,490,762)</b>
Taxation	21	21,021,601	(10,702,111)	19,250,213	-
<b>(Loss) / profit after taxation</b>		<b>(1,947,729)</b>	<b>119,233,937</b>	<b>28,209,742</b>	<b>(9,490,762)</b>
(Loss) / earning per share - basic and diluted		<b>(0.02)</b>	2.46	<b>0.30</b>	0.10

The annexed notes 1 to 26 form an integral part of these condensed interim financial statements.



Chief Executive

Director




Chief Financial Officer

## LIVEN PHARMA LIMITED

### CONDENSED INTERIM STATEMENT OF COMPREHENSIVE INCOME FOR THE HALF YEAR ENDED DECEMBER 31, 2025

Note	HALF YEAR ENDED		QUARTER ENDED	
	Un-audited December 31, 2025 (Rupees)	Un-audited December 31, 2024 (Rupees)	Un-audited December 31, 2025 (Rupees)	Un-audited December 31, 2024 (Rupees)
(Loss) / profit after taxation	(1,947,729)	119,233,937	28,209,742	(9,490,762)
<b>Other comprehensive income</b>				
Items that may be reclassified subsequently to profit or loss	-	-	-	-
Items that will not be reclassified to profit or loss	-	-	-	-
<b>Total other comprehensive income for the period</b>	-	-	-	-
<b>Total comprehensive (loss) / income for the period</b>	<b>(1,947,729)</b>	<b>119,233,937</b>	<b>28,209,742</b>	<b>(9,490,762)</b>

The annexed notes 1 to 26 form an integral part of these condensed interim financial statements.



Chief Executive



Director




Chief Financial Officer




**LIVEN PHARMA LIMITED**  
**CONDENSED INTERIM STATEMENT OF CHANGES IN EQUITY**  
**FOR THE HALF YEAR ENDED DECEMBER 31, 2025**

Particulars	Share capital	Capital reserve	Revenue reserve	Total equity
	Issued, subscribed and paid-up share capital	Surplus on revaluation of property, plant and equipment	Accumulated (loss)/profit	
	Rupees			
Balance as at July 1, 2024 (Audited)	121,237,000	38,056,582	(293,089,484)	(133,795,902)
Shares issued in accordance with scheme of merger	809,166,670	-	-	809,166,670
Impact of merger arrangement	-	-	109,680,240	109,680,240
<b>Comprehensive income for the period</b>				
Profit after taxation	-	-	119,233,937	119,233,937
Other comprehensive income for the period	-	-	-	-
<b>Total comprehensive income for the period</b>	-	-	119,233,937	119,233,937
Surplus relating to disposal net of deferred tax transferred to retained earnings	-	(38,056,582)	38,056,582	-
<b>Balance as at December 31, 2024 (Un-audited)</b>	<b>930,403,670</b>	<b>-</b>	<b>(26,118,725)</b>	<b>904,284,945</b>
Balance as at July 1, 2025 (Audited)	930,403,670	-	(296,543,276)	633,860,394
<b>Comprehensive income for the period:</b>				
Loss after taxation	-	-	(1,947,729)	(1,947,729)
Other comprehensive income for the period	-	-	-	-
<b>Total comprehensive loss for the period</b>	<b>-</b>	<b>-</b>	<b>(1,947,729)</b>	<b>(1,947,729)</b>
<b>Balance as at December 31, 2025 - (Un-audited)</b>	<b>930,403,670</b>	<b>-</b>	<b>(298,491,005)</b>	<b>631,912,665</b>

The annexed notes 1 to 26 form an integral part of these condensed interim financial statements.



Chief Executive

Director




Chief Financial Officer


**LIVEN PHARMA LIMITED**  
**CONDENSED INTERIM STATEMENT OF CASH FLOWS**  
**FOR THE HALF YEAR ENDED DECEMBER 31, 2025**

	Note	Un-audited December 31, 2025 (Rupees)	Un-audited December 31, 2024 (Rupees)
<b>CASH FLOWS FROM OPERATING ACTIVITIES</b>			
(Loss) / profit before taxation		(22,969,330)	129,936,048
<b>Adjustments for non cash and other items:</b>			
Depreciation on property, plant and equipment		12,115,743	9,092,656
Depreciation on right of use assets		629,481	-
Amortization on intangible assets		1,821,879	942,922
Impact of merger		-	(16,075,241)
Gain on disposal of fixed assets		(9,933,636)	(85,424,621)
Liability written off		-	(33,871,269)
Provision for obsolete stock		19,943,730	-
Allowance for expected credit loss		4,700,616	-
Finance cost		1,305,007	-
<b>Operating profit before working capital changes</b>		<b>7,613,490</b>	<b>4,600,495</b>
<b>Working capital changes</b>			
<b>Decrease / (increase) in current assets:</b>			
Stock in trade		(17,643,718)	(13,785,234)
Trade debts		(2,048,572)	(3,597,773)
Prepayments, deposits and advances		26,880	3,675
<b>(Decrease) / increase in current liabilities:</b>			
Trade and other payables		14,503,206	(656,802)
<b>Cash generated from / (used in) operations</b>	<b>A</b>	<b>2,451,286</b>	<b>(13,435,639)</b>
Finance cost paid		(1,330,717)	-
Taxes paid		(141,137)	-
<b>Net cash generated from / (used in) operating activities</b>		<b>979,432</b>	<b>(13,435,639)</b>
<b>CASH FLOWS FROM INVESTING ACTIVITIES</b>			
Adjustment of loan against disposal of fixed assets		-	205,080,348
Proceeds from disposal of property, plant and equipment		12,560,100	-
Payment for acquisition of intangible asset		-	(585,300)
Payments for acquisition of property, plant and equipment		(14,895,000)	(56,000)
<b>Net cash (used in) / generated from investing activities</b>	<b>B</b>	<b>(2,334,900)</b>	<b>204,439,048</b>
<b>CASH FLOWS FROM FINANCING ACTIVITIES</b>			
Payments against lease liabilities		(282,729)	-
Proceeds from running finance		50,921,419	-
Repayments against running finance		(52,961,784)	-
Loan received from related parties		408,148	11,049,173
Adjustment of loan against the disposal of fixed assets		-	(204,636,018)
Repayments against long term finance		(1,328,464)	-
<b>Net cash used in financing activities</b>	<b>C</b>	<b>(3,243,410)</b>	<b>(193,586,845)</b>
<b>Net decrease in cash and cash equivalents</b>	<b>A+B+C</b>	<b>(4,598,878)</b>	<b>(2,583,436)</b>
Opening cashflows of amalgamated entity		-	17,352,049
Cash and cash equivalents at the beginning of the period		7,884,396	38,000
<b>Cash and cash equivalents at the end of the period</b>		<b>3,285,518</b>	<b>14,806,613</b>

The annexed notes 1 to 26 form an integral part of these condensed interim financial statements.



Chief Executive



Director



Chief Financial Officer

